Abstract
Background: microRNAs are known to regulate various protein-coding gene expression posttranscriptionally. Fatty acids are cell membrane constituents and are also known to influence the biological activities of the cells like signal transduction, growth and differentiation of the cells, apoptosis induction, and other physiological functions. In our experiments, we used lauric acid to analyse its effects on human cancerous cell lines.
Objective: Our objective was to speculate the miRNA expression profile in lauric acid treated and untreated cancerous cell lines and further study the metabolic pathways of the targeted tumour suppressor and oncogenes.
Methods: The KB cells and HepG2 cells were treated with lauric acid and miRNA was isolated and the expression of tumour suppressor and oncogenic miRNA was measured by quantitative PCR. The untreated cells were used as control. The metabolic pathways of the target tumour suppressor and oncogenes were examined by GeneMANIA software.
Results: Interestingly, the lauric acid treatment suppresses the expression of oncogenic miRNA and significantly upregulated the expression of some tumour suppressor miRNAs. GeneMANIA metabolic pathway revealed that the upregulated tumour suppressor miRNAs regulate several cancer-associated pathways such as DNA damage, signal transduction p53 class mediator, stem cell differentiation, cell growth, cell cycle phase transition, apoptotic signalling pathway, cellular response to stress and radiation, etc. whereas oncogenic miRNAs regulate the cancer-associated pathway like cell cycle phase transition, apoptotic signalling pathway, cell growth, response to oxidative stress, immune response activating cell surface protein signalling pathway, cyclin-dependent protein kinase activity, epidermal growth factor receptor signalling pathways, etc.
Conclusion: In our study, we found that lauric acid works as an anticancer agent by altering the expression of miRNAs.
Keywords: miRNA, lauric acid, anticancer activity, metabolic pathways, tumour suppressor, oncogenes.
Graphical Abstract
[http://dx.doi.org/10.1007/s10495-008-0260-3] [PMID: 18785011]
[http://dx.doi.org/10.1016/j.jnutbio.2006.07.001] [PMID: 16963252]
[http://dx.doi.org/10.1146/annurev.nutr.19.1.63] [PMID: 10448517]
[http://dx.doi.org/10.1097/MCO.0b013e3282f52708] [PMID: 18301083]
[http://dx.doi.org/10.1177/0148607115595980] [PMID: 26177664]
[http://dx.doi.org/10.1007/s11746-014-2562-7]
[http://dx.doi.org/10.1093/nutrit/nuw002] [PMID: 26946252]
[http://dx.doi.org/10.3892/ol.2017.6195] [PMID: 28693220]
[http://dx.doi.org/10.1159/000356067] [PMID: 24356281]
[http://dx.doi.org/10.1038/nrg3198] [PMID: 22510765]
[http://dx.doi.org/10.1038/nrm3611] [PMID: 23800994]
[http://dx.doi.org/10.1038/ncb2115] [PMID: 20935637]
[http://dx.doi.org/10.1038/nrc1840] [PMID: 16557279]
[http://dx.doi.org/10.3892/or.2015.4336] [PMID: 26496897]
[http://dx.doi.org/10.1016/0022-1759(83)90303-4] [PMID: 6606682]
[http://dx.doi.org/10.1006/meth.2001.1262] [PMID: 11846609]
[http://dx.doi.org/10.1016/j.bbamem.2013.12.021] [PMID: 24388951]
[http://dx.doi.org/10.1002/jcb.28345] [PMID: 30816573]
[http://dx.doi.org/10.3892/mmr.2019.9952] [PMID: 30816471]
[http://dx.doi.org/10.1038/cddiscovery.2017.63] [PMID: 28924490]
[http://dx.doi.org/10.3390/molecules24112034] [PMID: 31141939]
[http://dx.doi.org/10.1016/j.biopha.2016.12.123] [PMID: 28068634]
[http://dx.doi.org/10.1016/j.imr.2018.05.001] [PMID: 30271714]
[http://dx.doi.org/10.13040/IJPSR.0975-8232.7(5).1948-55]
[http://dx.doi.org/10.1016/j.semcancer.2019.02.003] [PMID: 30742906]
[http://dx.doi.org/10.2174/1871520619666191021160752] [PMID: 31736449]
[http://dx.doi.org/10.1016/j.ejphar.2019.01.006] [PMID: 30639311]
[http://dx.doi.org/10.5037/jomr.2011.2201] [PMID: 24421988]
[http://dx.doi.org/10.1038/mt.2009.207] [PMID: 19738602]
[http://dx.doi.org/10.1073/pnas.0800121105] [PMID: 18362358]
[http://dx.doi.org/10.1177/1010428317698379] [PMID: 28459366]
[http://dx.doi.org/10.1007/s12032-009-9344-3] [PMID: 19908170]
[http://dx.doi.org/10.1158/1940-6207.CAPR-11-0267] [PMID: 21836020]
[http://dx.doi.org/10.1073/pnas.0506654102] [PMID: 16166262]
[PMID: 30657555]
[PMID: 28982852]
[http://dx.doi.org/10.1016/j.bbrc.2017.03.110] [PMID: 28342862]
[http://dx.doi.org/10.18632/oncotarget.12190] [PMID: 27677076]
[http://dx.doi.org/10.1074/jbc.M112.395947] [PMID: 23188821]
[http://dx.doi.org/10.1038/s41598-018-26360-1] [PMID: 29789629]
[http://dx.doi.org/10.1158/0008-5472.CAN-10-1001] [PMID: 21098710]
[http://dx.doi.org/10.1007/s11427-012-4384-x] [PMID: 23108868]
[http://dx.doi.org/10.1158/1078-0432.CCR-08-3053] [PMID: 19509158]
[PMID: 23564792]
[http://dx.doi.org/10.1093/cvr/cvp015] [PMID: 19147652]
[http://dx.doi.org/10.1016/j.oraloncology.2013.03.430] [PMID: 23602254]
[http://dx.doi.org/10.1158/1541-7786.MCR-14-0703] [PMID: 25758165]
[http://dx.doi.org/10.1016/j.livres.2018.06.002]
[http://dx.doi.org/10.1038/sj.bjc.6605958] [PMID: 20978511]
[http://dx.doi.org/10.4161/cbt.10.12.14252] [PMID: 21139417]
[http://dx.doi.org/10.3892/ol.2014.2816] [PMID: 25663852]
[http://dx.doi.org/10.1158/0008-5472.CAN-14-2218] [PMID: 26062558]
[http://dx.doi.org/10.3389/fimmu.2017.01182] [PMID: 28993774]